TRVI - Trevi Therapeutics Inc (Healthcare: Biotechnology) Projected Earnings Date: 0000-02-29    (Delayed quote data   2026-03-24)
Last
 10.64		 Change
 ⇓ -0.12   (-1.12%)		 Volume
  1,323,901
Open
 10.63		 High
 10.71		 Low
 10.25
8EMA (Daily)
 10.91		 40EMA (Daily)
 11.31		 50EMA (Daily)
 11.32		 STO (Daily)
 8.430		 MACD Hist (Daily)
 -0.147
8EMA (Weekly)
 11.148		 40EMA (Weekly)
 9.95		 50EMA (Weekly)
 9.41		 STO (Weekly)
 38.261		 MACD Hist (Weekly)
 -0.206
Company Profile
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2026 OptionChance.com